​
​

Akebia Therapeutics (AKBA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Akebia Therapeutics Revenue Highlights

Latest Revenue (Y)

$194.62M

Latest Revenue (Q)

$35.59M

Main Segment (Y)

Product

Main Geography (Y)

Product

Akebia Therapeutics Revenue by Period

Akebia Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$194.62M-33.49%
2022-12-31$292.60M37.00%
2021-12-31$213.58M-27.68%
2020-12-31$295.31M-11.85%
2019-12-31$335.00M61.26%
2018-12-31$207.74M16.72%
2017-12-31$177.98M11495.05%
2016-12-31$1.53M100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31--

Akebia Therapeutics generated $194.62M in revenue during NA 2023, up -33.49% compared to the previous quarter, and up 93.68% compared to the same period a year ago.

Akebia Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$35.59M-18.46%
2024-06-30$43.65M33.86%
2024-03-31$32.61M-41.98%
2023-12-31$56.20M33.65%
2023-09-30$42.05M-25.42%
2023-06-30$56.38M40.49%
2023-03-31$40.13M-27.28%
2022-12-31$55.18M12.70%
2022-09-30$48.96M-61.37%
2022-06-30$126.76M105.45%
2022-03-31$61.70M3.51%
2021-12-31$59.60M22.25%
2021-09-30$48.76M-7.86%
2021-06-30$52.91M1.16%
2021-03-31$52.30M-7.75%
2020-12-31$56.70M-5.48%
2020-09-30$59.99M-33.45%
2020-06-30$90.14M1.88%
2020-03-31$88.48M27.21%
2019-12-31$69.56M-24.38%
2019-09-30$91.98M-8.76%
2019-06-30$100.80M38.72%
2019-03-31$72.67M21.41%
2018-12-31$59.85M12.57%
2018-09-30$53.17M8.97%
2018-06-30$48.79M6.23%
2018-03-31$45.93M-47.40%
2017-12-31$87.32M111.51%
2017-09-30$41.28M44.75%
2017-06-30$28.52M36.69%
2017-03-31$20.86M1259.28%
2016-12-31$1.53M100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31--

Akebia Therapeutics generated $35.59M in revenue during Q3 2024, up -18.46% compared to the previous quarter, and up 63.13% compared to the same period a year ago.

Akebia Therapeutics Revenue Breakdown

Akebia Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Product$170.30M$177.07M$142.22M$128.90M$111.12M
License Collaboration And Other Revenue$24.32M$115.53M$71.36M$166.41M$223.88M

Akebia Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (87.50%), and License Collaboration And Other Revenue (12.50%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
License Collaboration And Other Revenue$1.84M$1.60M$4.89M$14.13M$5.30M$5.50M$6.72M$83.06M$20.25M$17.51M$12.00M$19.95M$21.90M$22.09M$25.60M$59.45M$59.27M$40.64M$10.00M-
Product$35.59M$31.01M$93.23M$42.24M$34.83M$49.68M$42.24M$43.70M$41.45M$42.10M$36.75M$32.96M$30.41M$34.60M$34.39M$30.70M$29.21M$28.91M$30.00M-

Akebia Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (95.09%), and License Collaboration And Other Revenue (4.91%).

Akebia Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 22Dec 21Dec 20Dec 19Dec 18
Product$177.07M$142.22M$128.90M$111.12M-
License Collaboration And Other Revenue$115.53M$71.36M$166.41M$223.88M$200.47M

Akebia Therapeutics's latest annual revenue breakdown by geography, as of Dec 22: Product (60.51%), and License Collaboration And Other Revenue (39.49%).

Quarterly Revenue by Country

CountryMar 23Jun 20
License Collaboration And Other Revenue$5.30M-
Product$34.83M-
Non-US-$65.00M

Akebia Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Product (86.79%), and License Collaboration And Other Revenue (13.21%).

Akebia Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
AKBAAkebia Therapeutics$194.62M$35.59M
MCRBSeres Therapeutics$126.33M-
CDTXCidara Therapeutics$63.91M-
CWBRCohBar--
XFORX4 Pharmaceuticals-$560.00K
AVROAVROBIO--
ELEVElevation Oncology--
OCEAOcean Biomedical--
HEPAHepion Pharmaceuticals--
ENVBEnveric Biosciences--

AKBA Revenue FAQ

What is Akebia Therapeutics’s yearly revenue?

Akebia Therapeutics's yearly revenue for 2023 was $194.62M, representing a decrease of -33.49% compared to 2022. The company's yearly revenue for 2022 was $292.6M, representing an increase of 37.00% compared to 2021. AKBA's yearly revenue for 2021 was $213.58M, representing a decrease of -27.68% compared to 2020.

What is Akebia Therapeutics’s quarterly revenue?

Akebia Therapeutics's quarterly revenue for Q3 2024 was $35.59M, a -18.46% decrease from the previous quarter (Q2 2024), and a -15.35% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $43.65M, a 33.86% increase from the previous quarter (Q1 2024), and a -22.58% decrease year-over-year (Q2 2023). AKBA's quarterly revenue for Q1 2024 was $32.61M, a -41.98% decrease from the previous quarter (Q4 2023), and a -18.74% decrease year-over-year (Q1 2023).

What is Akebia Therapeutics’s revenue growth rate?

Akebia Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -8.87%, and for the last 5 years (2019-2023) was -41.90%.

What are Akebia Therapeutics’s revenue streams?

Akebia Therapeutics's revenue streams in c 23 are Product, and License Collaboration And Other Revenue. Product generated $170.3M in revenue, accounting 87.50% of the company's total revenue, down -3.82% year-over-year. License Collaboration And Other Revenue generated $24.32M in revenue, accounting 12.50% of the company's total revenue, down -78.95% year-over-year.

What is Akebia Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Akebia Therapeutics was Product. This segment made a revenue of $170.3M, representing 87.50% of the company's total revenue.